Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2008

View Archived Issues

Recent patent literature describes novel treatment options for diabetes

New compounds for treating HCV infection disclosed in recent patents

New therapeutic agents for respiratory disorders reported in recent patent literature

Novel antibiotic shows promising in vitro and in vivo activity against Gram-positive pathogens

Clinical Data initiates second of two phase III trials of vilazodone for depression

FDA to review Lev's BLA for Cinryze in hereditary angioedema

Glycotex completes enrollment in phase IIa study of GLYC-101 for wound healing

Cytopia presents an update on phase II, phase I and preclinical development of CYT-997

Oncolys and Tacere sign alliance and license agreement for Asia for HCV drug

Calando submits IND to FDA to initiate phase I clinical trial of CALAA-01 in cancer

Preclinical results of TRPV1 antagonist GRC-6211 reported

GSK's novel NOS-2 inhibitor SB-823387 shows analgesic efficacy in experimental dental pain

Preclinical profile of cis-ACCP, a novel MMP inhibitor with antimetastatic properties

FDA recommends approval of Amgen's BLA for romiplostim in immune thrombocytopenic purpura

Millennium announces publication of clinical results of phase I/II Velcade trial in multiple myeloma

Dosing initiated in obesity trial with oxyntomodulin analogue TKS-1225

Genentech to initiate three phase II clinical trials of GDC-0449 in 2008

Arana begins phase II trial for lead anti-TNF drug candidate

PregLem commences SAPHIR study for steroid sulfatase inhibitor PGL-2001

Raven initiates phase II RAV-12 trial in metastatic pancreatic cancer

Cardiome announces positive interim phase IIb results for oral vernakalant

Positive efficacy data from EndoTAG-1 phase II clinical trial in pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...